BlackRock Health Sciences Opportunities Portfolio (BME)
NYSE NYSE Primary NASDAQ (NMS) 
B&M shares slide but analysts say quarter changes little
B&M European Value Retail SA (LSE:BME) shares fell after the discount retailer reported a decline in underlying UK sales, although analysts said the update was largely in line with expectations and did little to alter the investment case. Shares in the FTSE 250-listed group fell 5.8% to 192.1p by early afternoon on Wednesday.
B&M reports improved UK trading and strong sales in France
B&M European Value Retail SA (LSE:BME) reported first-quarter sales growth of 2% as strong trading in France and steady growth at Heron Foods helped lift group revenue despite weaker trading in its core UK business. The discount retailer said revenue rose to £1.43 billion in the 13 weeks to 27 June from a year earlier.
Broker puts B&M under review and warns re-rating is unlikely despite shares surging 15.5%
B&M European Value Retail SA (LSE:BME) shares surged 15.5% to 196.9p after full-year results came in line with guidance, but Shore Capital has placed the discount retailer under review and cautioned that the conditions for a meaningful re-rating are not yet in place. The broker, which had previously held a 'buy' rating on the stock, acknowledged that the financial year to March represented progress after what management itself described as a difficult year.
B&M profits slump as discounter pushes turnaround plan
B&M European Value Retail SA (LSE:BME) reported a 38% fall in annual profits as weak trading in the UK was exacerbated by "execution issues", though it said its turnaround programme is beginning to show signs of progress. The FTSE 250-listed discount retailer posted adjusted profit before tax of £284 million for the 2026 financial year, down from £455 million a year earlier, whjile adjusted EBITDA fell 26% to £459 million.
Deutsche Bank downgrades B&M and Wickes as retailers brace for consumer pressure
Deutsche Bank has downgraded B&M European Value Retail SA (LSE:BME) and Wickes Group PLC (LSE:WIX) from 'hold' to 'sell', cutting price targets sharply as inflationary headwinds threaten to test consumer spending and retailer margins more severely. B&M's target was cut from 175p to 155p, while Wickes Group saw its target slashed from 235p to 165p, reflecting analyst Adam Cochrane's concern about the timing and intensity of upcoming demand erosion.
BME: Discount Narrows, But A Strong Long-Term Hold Candidate Anyway
BlackRock Health Sciences Trust remains a steady income generator, never having cut its regular distribution since inception, despite recent lackluster results. BME's discount has narrowed, resulting in some outperformance relative to XLV on total share price return. I continue to hold BME for long-term income, viewing the current healthcare sector undervaluation as a potential opportunity for cautious, incremental additions.
BME: Removal Of Option Writing Can Improve NAV Growth (Rating Upgrade)
BlackRock Health Sciences Trust is upgraded to a buy, benefiting from its shift to an equity-focused strategy and improved NAV growth prospects. BME offers an 8.3% monthly dividend yield, but coverage is inconsistent and reliant on net realized gains rather than stable investment income. Elimination of the option writing strategy positions BME to better capture upside in healthcare, especially with exposure to GLP-1 drug market leaders.
B&M: Brokers split on the outlook for struggling discount retailer
B&M European Value Retail SA (LSE:BME) is being judged from two angles by the City, with Deutsche Bank turning more cautious on the cost of its turnaround while Shore Capital argues the risks are already priced in. Deutsche has cut its price target to 175p from 180p and reiterated its 'hold' rating, leaving the shares trading close to fair value after their recent recovery.
B&M pares losses as analysts see encouraging progress with turnaround
Shares in B&M European Value Retail SA (LSE:BME) fell 2% in early trading after a third profits warning in four months, but pared losses as analysts said management appeared to be making progress in the turnaround. The third-quarter trading update, covering the 13 weeks to 27 December, revealed that group sales increased 2.9%, driven by contributions from new space, partly offset by a 0.6% decline in UK like-for-likes.
B&M issues third profit warning in four months
B&M European Value Retail SA (LSE:BME) has issued its third profit warning since last summer as the discounter's rejigged board struggles to turn around performance. The discount retailer now expects adjusted EBITDA for the year to March of £440-475 million, down from previous guidance of £470-520 million, due to investments in pricing, stock clearance of discontinued lines, and the financial underperformance of Heron Foods.
BME: Attractive Discount With Steady Monthly Distribution
BlackRock Health Sciences Trust has seen some strong performance recently, yet still trades at a -7.8% discount to NAV, offering compelling value. BME removed its options-writing strategy, eliminating upside caps and shifting focus to long-term capital appreciation in health sciences equities. Despite sector volatility and UNH headwinds, BME remains diversified in healthcare exposure, but some concentration in top holdings like LLY.
BME: Monthly Income With Upside From The Out-Of-Favor Healthcare Sector
I rate BlackRock Health Sciences Trust a Buy for income-focused investors seeking long-term, buy-and-hold exposure to blue-chip healthcare stocks. BME trades at a -7.8% discount to NAV and offers a monthly distribution yielding approximately 8%, supported by consistent, rising dividends. Recent political pressure on healthcare has depressed valuations, but I expect portfolio holdings like Eli Lilly and UnitedHealth to rebound as regulatory focus wanes.
